nivolumab compared to docetaxel in patients with nsclc
Published 9 years ago • 509 plays • Length 1:14Download video MP4
Download video MP3
Similar videos
-
2:22
dr. borghaei on 2-year findings with nivolumab vs docetaxel in nsclc
-
4:04
update from checkmate 057: nivolumab versus docetaxel in advanced non-squamous nsclc
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
17:30
immunotherapy in lung cancer: panacea vs. reality?
-
4:22
nivolumab in non-small cell lung cancer
-
6:06
atezolizumab monotherapy vs docetaxel in 2nd and 3rd line nsclc
-
1:49
adverse events of nivolumab in patients with advanced, non-squamous nsclc
-
5:17
personalized cancer vaccines may train the body’s immune system to fight tumors
-
1:03
dr. herbst on combination of nivolumab and ipilimumab in patients with nsclc
-
3:17
nivolumab with ipilimumab for small cell lung cancer
-
2:08
why checkmate-026 failed to show pfs improvement with nivolumab in lung cancer
-
5:49
nivolumab extends survival for patients with the most common lung cancer
-
25:26
locally advanced nsclc: combination therapy with targeted and immunotherapy agents
-
8:23
nivolumab extends survival for nsclc
-
0:57
nivolumab/ docetaxel shows promise for nsclc in checkmate 057 trial
-
1:19
five-year follow-up results for nivolumab in nsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
6:03
checkmate 9la: nivolumab, ipilimumab and chemotherapy for stage iv nsclc
-
1:39
sotorasib shows superior pfs and orr compared to docetaxel for nsclc